Skip to main content
. Author manuscript; available in PMC: 2016 Apr 25.
Published in final edited form as: Eur J Cancer. 2016 Feb 12;56:162–171. doi: 10.1016/j.ejca.2015.12.022

Fig. 2.

Fig. 2

Composite change for the Functional Assessment of Cancer Therapy-Taxane subscale at baseline and prior to dosing on day 1 of each cycle on a randomized phase III clinical trial comparing nab-paclitaxel/carboplatin (nab-PC) versus solvent-based paclitaxel/carboplatin (sb-PC) in patients with newly diagnosed advanced non-small cell lung cancer. Larger bars represent greater deteriorations from baseline as perceived by patients. Reprinted with permission from J Thorac Oncol. 2014;9: 83–90.